InnoCare Pharma (HKG: 9969; SHA: 688428) announced today that the first patient has been dosed in the registrational Phase III head‑to‑head clinical trial of the Company’s novel BCL2 inhibitor mesutoclax (ICP‑248) in combination with azacitidine versus venetoclax in combination with azacitidine for the treatment of elderly or unfit patients with treatment‑naïve acute myeloid leukemia (AML).
Trial Initiation Milestone
| Item | Detail |
|---|---|
| Company | InnoCare Pharma (HKG: 9969; SHA: 688428) |
| Trial Type | Registrational Phase III, head‑to‑head |
| Investigational Regimen | Mesutoclax (ICP‑248) + azacitidine |
| Comparator Regimen | Venetoclax + azacitidine |
| Patient Population | Elderly or unfit patients with treatment‑naïve acute myeloid leukemia (AML) |
| Status | First patient dosed |
| Announcement Date | 9 Nov 2026 |
| Regulatory Designation | Mesutoclax has been granted two Breakthrough Therapy Designations (BTDs) by China’s CDE |
Drug Profile & Mechanism of Action
- Molecule: Mesutoclax (ICP‑248) – a novel, oral, highly selective BCL2 inhibitor developed in‑house by InnoCare.
- Mechanism: Exerts anti‑tumor activity by selectively inhibiting BCL2 and restoring the normal apoptosis process in cancer cells.
- Selectivity Advantage: High selectivity for BCL2 is designed to drive potent apoptotic activity in malignant cells; head‑to‑head positioning against venetoclax will directly test differentiation within the class.
- Regulatory Recognition: Two CDE Breakthrough Therapy Designations underscore the unmet medical need addressed in B‑cell lymphomas and myeloid malignancies.
Clinical Pipeline – Mesutoclax Development Status
| Trial | Indication / Setting | Regimen | Status |
|---|---|---|---|
| Registrational Phase III | 1L chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) | Mesutoclax + orelabrutinib | Patient enrollment completed |
| Registrational Phase II | BTK inhibitor‑treated mantle cell lymphoma (MCL) | Mesutoclax | Patient enrollment completed |
| Registrational Phase III | Relapsed/refractory marginal zone lymphoma (r/r MZL) | Mesutoclax + orelabrutinib | Accelerating |
| Registrational Phase III | Relapsed/refractory mantle cell lymphoma (r/r MCL) | Mesutoclax + orelabrutinib | Accelerating |
| Registrational Phase III | Treatment‑naïve AML (elderly or unfit) | Mesutoclax + azacitidine vs. venetoclax + azacitidine | First patient dosed |
Industry Context – BCL2 Inhibition in AML
- Standard of Care: The combination of venetoclax with azacitidine is the established backbone for elderly or unfit patients with newly diagnosed AML who are ineligible for intensive chemotherapy – making it the natural comparator in a registrational head‑to‑head design.
- Apoptosis Pathway: BCL2 inhibition releases pro‑apoptotic proteins in leukemia cells, and hypomethylating agents such as azacitidine act synergistically to lower the apoptotic threshold.
- Head‑to‑Head Strategy: A positive registrational readout versus venetoclax would provide direct comparative evidence – a differentiator in an increasingly competitive BCL2 class.
Market Impact & Outlook
- Pivotal AML Expansion: First‑patient‑dosed in the registrational Phase III marks mesutoclax’s formal entry into the myeloid malignancy registrational arena, complementing its advanced lymphoma program.
- Pipeline Breadth: With five registrational trials spanning AML, CLL/SLL, MCL, and MZL – two already fully enrolled – mesutoclax is emerging as a franchise asset across B‑cell and myeloid malignancies.
- Combination Synergy with Orelabrutinib: Multiple trials pair mesutoclax with InnoCare’s own BTK inhibitor orelabrutinib, creating an internally controlled combination strategy with potential co‑commercialization advantages.
- Competitive Positioning: Success in the head‑to‑head setting could position mesutoclax as a next‑generation alternative to venetoclax in China’s large AML patient population, with two BTDs supporting accelerated regulatory pathways.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the registrational Phase III head‑to‑head trial of mesutoclax plus azacitidine versus venetoclax plus azacitidine, the progression of mesutoclax trials in CLL/SLL, MCL, and MZL, and potential regulatory filings. Actual results may differ due to risks including clinical trial outcomes, comparative efficacy and safety versus venetoclax, regulatory review timelines, and competitive dynamics in the BCL2 inhibitor class.-Fineline Info & Tech
